One group combined CRISPR/Cas9 with an adeno-associated virus (AVV)-mediated gene-delivery approach to insert anti-CD33 CAR to a safe-harbor locus of primary NK cells, acquiring a mean expression of 68% CAR-positive NK cells and enhanced anti-AML activity [294]. This evidence concerns the gene CD33 and acute myeloid leukemia.